- Original investigation
- Open Access
Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats
© Lu et al; licensee BioMed Central Ltd. 2010
- Received: 19 February 2010
- Accepted: 19 May 2010
- Published: 19 May 2010
Endothelial dysfunction precedes atherogenesis and clinical complications in type 2 diabetes. The vascular dysfunction in Zucker diabetic fatty (ZDF) rats was evaluated at different ages along with the effect of treatment with rosiglitazone (Rosi) on endothelial function and mechanical remodeling.
The Rosi treatment was given to ZDF rats for 3 weeks. The endothelium-dependent vasodilation and α-adrenoceptor-dependent vasoconstriction of femoral arteries were studied using an ex-vivo isovolumic myograph. The biomechanical passive property of the arteries was studied in Ca2+-free condition. The expressions of endothelial nitric oxide synthase (eNOS), α-adrenoceptor, matrix metalloproteinase 9 (MMP9), and elastase were evaluated.
Endothelium-dependent vasorelaxation of the femoral artery was blunted at low doses in ZDF rats at 11 weeks of age and attenuated at all doses in ZDF rats at 19 weeks of age. The expression of eNOS was consistent with the endothelium-dependent vasorelaxation. The α-adrenoceptor was activated and the mechanical elastic modulus was increased in ZDF rats at 19 weeks of age. The expressions of α-adrenoceptor, MMP9, and elastase were up regulated in ZDF rats at 19 weeks of age. Rosi treatment for 3 weeks restored endothelium-dependent vasorelaxation and the expression of eNOS and the adrenoceptor activation at the doses below 10-6 mole/L in ZDF rats at 19 weeks of age. Rosi treatment for 3 weeks did not, however, improve the mechanical properties of blood vessel, the expressions of α-adrenoceptor, MMP9, and elastase in ZDF rats.
The endothelial dysfunction and mechanical remodeling are observed as early as 19 weeks of age in ZDF rat. Rosi treatment for 3 weeks improves endothelial function but not mechanical properties.
- Endothelial Dysfunction
- Endothelial Function
- Vascular Remodel
- Superficial Femoral Artery
Cardiovascular disease (CVD) is the major cause of mortality and morbidity in people with type 2 diabetes mellitus (T2DM) and macrovascular disease is the leading cause of mortality in T2DM [1–7]. Endothelial dysfunction is a significant biomarker of early stage of CVD, which can be detected functionally as changes in vasomotor responses, cell proliferation, platelet adhesion/aggregation, vascular permeability, or leucocyte/endothelial interaction [6, 8–10]. T2DM and its companion complications (atheroscleropathy) are associated with multiple metabolic toxicities and chronic injurious stimuli that result in vascular remodeling, including fibrosis, structural derangement, tissue or organ dysfunction, and ultimate failure as a result of loss of form (structure) and function [1, 4, 11]. Endothelial dysfunction is considered as one of the instigators of atherosclerosis during the development of T2DM and the major cause of vascular remodeling triggered by increase of growth factor release ranging from platelets to leucocytes which trigger the pathway of reactive oxygen species (ROS), and imbalance of matrix metalloproteinase (MMPs) and the collagens within vascular extracellular matrix (ECM) [1, 10, 11]. The changes in biomechanical properties have been documented in diabetes which reflect the micro-structural remodeling (elastin and collagen) of the vessel wall [12–17]. The endothelial dysfunction in T2DM can be improved with drug treatment through renin-angiotensin system blockers, β-blockers, Calcium antagonists, and others . The drugs for lipid management have been shown to reduce macrovascular disease and improve endothelial function . Both endothelial and vascular smooth muscle cells are involved in the remodeling of vessel wall in diabetes [11, 16, 18].
It is widely reported that vascular function is compromised in ZDF rat which is a well-established T2DM animal model [5, 19, 20]. Thiazolidinediones (TZD) act as agonists of the peroxisome proliferation-activated receptor γ (PPARγ), improve insulin resistance, and reduce free fatty acid (FFA) in patients with T2DM [20, 21]. The TZD rosiglitazone (Rosi) enhances endothelial function and increases nitric oxide (NO) release in patients with T2DM [21, 22]. Rosi has also been reported to improve endothelium-dependent vascular dysfunction in ZDF rats .
It is unclear if the remodeling of mechanical property of the vessel wall is reversed in T2DM animal model along with improvement of endothelial function with Rosi treatment in short term. In present study, we measured the endothelial function with a novel myograph and biomechanical properties (stress-strain relationship) of femoral artery in ZDF rats with/without Rosi treatment and their age-match groups. The biomarkers, including vascular reactivation and expression of eNOS (for endothelial functions), α-adrenoceptor (for vascular remodeling and smooth muscle hypertrophy), MMP9 (for remodeling of basement membrane of blood vessel), and elastase (for remodeling of extracellular matrices, especially elastin), were also evaluated in this study.
The animal experiments were performed in accordance with the guidelines of Institute of Laboratory Animal Research Guide, Public Health Service Policy, Animal welfare Act, and an approved PreClinOmics IACUC protocol.
Animals and treatments
Zucker diabetic fatty (ZDF) and Zucker lean littermate rats were obtained from Charles River. ZDF and lean rats were fed with a commercial rodent chow Purina 5008 ad libitum. The body weight was measured weekly. The baseline glucose and triglycerides were measured in whole blood taken from the tail vein in the morning of the terminal study. The animals were randomly divided into age-matched and compound-treated groups. Age-matched groups had two subgroups: 11-weeks and 19-weeks. There were vehicle and rosiglitazone (Rosi) treated groups from 16 weeks to 19 weeks of age. The vehicle treated group was orally gavaged with 1% CMC/0.25% Ten 80 at 10 ml/kg. The compound Rosi treated group was given 3 mg/kg/day Rosi in vehicle in the morning by oral gavage as outlined in previous reports [5, 20].
Tissue preparation and isovolumic myograph
On the day of termination, the rat was weighed and blood was sampled. The animal was anesthetized with isoflurane. The left superficial femoral artery (SFA) was cannulated to measure physiologic pressure, which indicates the blood pressure in a small artery (outer diameter of SFA is about 0.4 mm). The right common femoral artery was excised quickly and placed in cold physiological saline solution (PSS in mmole/L: 119 NaCl, 4.7 KCl, 25 NaHCO3, 1.17 KH2PO4, 1.17 MgSO4, 1.6 CaCl, 5.5 Dextrose, solution gassed by 95% O2 5% CO2). The animal was euthanized by overanesthesia with isoflurane. The left common femoral artery was excised and stored at -30°C for detection of protein expression. The branches on the right common femoral artery were ligated and the vessel was cannulated with connectors. The vessel was warmed up to 37°C slowly (20 - 25 min) and equilibrated for 40 minutes at a transmural pressure of 15 mmHg and in situ length.
The isovolumic system consisted of a chamber with two connectors which bridge the blood vessel and thick-wall tubes . A volume compensator injected PSS into the vessel to offset the permeability of the vessel wall to maintain constant volume (i.e., isovolumic myograph). The aerated (95% O2 5% CO2) PSS filled the chamber tubes before vessel cannulation. The vessel was inflated to a desired pressure, e.g., physiologic pressure. To achieve an isovolumic condition, a clamp placed on the tube between the pressurized flask and the connector was closed and the PSS in the lumen of the vessel and tubes was sealed. The vascular contraction or relaxation in response to chemical stimulation was characterized by change of intraluminal pressure while the vessel diameter was tracked simultaneously.
Vascular functions in response to agonist/antagonist
The dose-response vasoconstriction to phenylephrine (PE, an agonist of α-adrenoceptor) was performed to evaluate the activation of α-adrenoceptor (10-11 to 10-4 mole/L). To evaluate endothelium-dependent dose-response relaxation to acetylcholine (ACh, 10-12 to 10-5 mole/L) or endothelium-independent dose-response relaxation to sodium nitroprusside (SNP, 10-9 to 10-5 mole/L), the vessel was pre-constricted with sub-maximal dose of PE. KCl (60 mM) was added to the bath to test vessel viability. Since diabetes and hypertension are common co-morbidities, we investigated the synergistic effect of acute over-inflation in the diabetic vessels on endothelial function. The artery was stretched to physiologic axial stretch ratio of 1.3 and inflated to a hypertensive level (170% of physiological pressure). The endothelium-dependent (ACh) and -independent (SNP) relaxations were performed according to the above protocol.
where A 0 is the cross-sectional wall area of vessel at no-load state (zero transmural pressure) and λ is axial stretch ratio.
Passive mechanical properties
where ε physio is the circumferential strain at physiological state.
Expressions of eNOS, α-adrenoceptor, MMP9, and elastase
Briefly, the protein extracts (~25 μg) from arterial tissues were fractionated on 10% SDS-PAGE gel, transferred onto polyvinylidene difluoride membrane, and probed with the following primary antibodies: anti-eNOS (BD transduction laboratory), anti-α-adrenoceptor (ABCam), anti-MMP9 and anti-elastase (Santa Cruz Biotech). Blots were incubated with horseradish peroxidase-conjugated secondary antibody. The signal was detected by enhanced chemiluminescence (ECL, Amersham) and evaluated by densitometry (Sigma Scan). β-actin was used for normalization.
The data were presented as mean ± SD. Significant differences between two data points were determined by student t-test. Significant differences between the dose-dependent groups and stress-strain relationship were determined by use of Analysis Of Variance (ANOVA) between groups. A probability of p < 0.05 was considered to be indicative of a statistically significant difference.
Effect of age and the treatment of Rosiglitazone on body weight, average arterial pressure, blood glucose, and triglycerides.
Number of Animals
Age of Animal (weeks)
11.8 ± 1.2
11.3 ± 0.9
19.7 ± 1.5
19.2 ± 1.1
19.6 ± 1.5
19.3 ± 1.2
Average Pressure (mmHg)
69.2 ± 8.9
71.7 ± 9.3
72.2 ± 9.7
74.8 ± 11.6
71.9 ± 10.3
73.9 ± 11.8
Body Weight (grams)
339 ± 38
369 ± 35
382 ± 35
401 ± 37*
403 ± 29*
423 ± 33*
112.8 ± 16.1
457.8 ± 35.9*
116.3 ± 15.0
431.4 ± 30.3*
472.0 ± 46.0*
445.6 ± 48.8*
108.3 ± 11.9
583.4 ± 49.5*
121.8 ± 16.5
602.6 ± 59.7*
609.1 ± 79.7*
613.1 ± 46.5*
In present study, the endothelium-dependent vasorelaxation in response to ACh was attenuated and the expression of eNOS down regulated in ZDF rats at 19 weeks of age in comparison to Zucker lean rats. The acute over-inflation (simulates acute hypertension) compromised the endothelium-dependent relaxation of artery in both ZDF and lean rats but more so in the ZDF rats. The passive stress-strain relationships reflect the biomechanical properties of blood vessel and a leftward shift suggests an increased elastic modulus at 19 weeks of age in ZDF rats. This is consistent with our previous observation of stiffer arteries in streptozotocin-induced diabetes . The treatment for 3 weeks of Rosi improved endothelial function but did not alter the passive mechanical properties. The up regulations of α-adrenoceptor, MMP9, and elastase, provide further evidence of vascular remodeling in ZDF rats with/without Rosi treatment.
ZDF rats are inbred from a colony of obese Zucker rats with a hyperglycemic phenotype. The blood glucose in all fatty males of ZDF rat model increases more than 4-fold by 10 weeks of age when fed Purina 5008 and remains at this high level throughout their lifespan. Although between 10-13 weeks of age, the serum insulin is elevated, it declines progressively with advancing age. Between 22-42 weeks of age, serum insulin levels decline to below the levels of insulin in age-matched lean control rats due to pancreatic beta cell failure and renal injury develops . In the present study, the ages of the animals were selected at 11 weeks of age at the initiation of hyperglycemia and at 19 weeks of age when diabetic complications had not significantly occurred. Endothelial dysfunction has been reported in ZDF rats at 16-24 weeks in coronary artery and over 22 weeks in aorta [5, 8].
Here, we report endothelial dysfunction in significantly younger rats in the common femoral artery. Endothelial dysfunction of common femoral artery was detected in ZDF rats as early as 11 weeks in response to low concentration of ACh which may be attributed to the more physiologic loading in both inflation and axial elongation. Hypertension is very frequent among T2DM . The occurrence of diabetes and hypertension are multiplicative risk factors for macro- and micro- vascular diseases and endothelial dysfunction is considered as one of the biomarkers of atherosclerosis during the development of T2DM . Our results show that acute hypertension causes profound endothelial dysfunction in ZDF rat. Hence, distension of a ZDF vessel causes a confounding deleterious effect on endothelial function.
The vasoconstriction in response to PE may reflect the activation of the α-adrenoeceptor. The up regulation of α-adrenoceptor's activation and expression implies vascular hypertrophy and remodeling [25–27]. T2DM often lead to matrix deposition and glycation in blood vessel wall, particularly those proteins associated with the basement membrane, and increase in stiffness or decrease in distensibility of blood vessel . The up regulation of MMP9 indicates matrix remodeling and especially the remodeling of basement membrane. The increased expression of elastase reflects degradation of elastin fibers and hence increased stiffness of the vessel wall.
Rosi treatment restored the compromised endothelium-dependent vasorelaxation in ZDF rats at the 19 weeks of age while plasma glucose and serum triglycerides remaining at high concentration consistent with previous observations [21, 28, 29]. It has been suggested that Rosi may prevent free fatty acid-induced endothelial dysfunction and exert anti-inflammatory and antioxidative effects directly in the vasculature [20, 30–33]. In this study, we found that Rosi treatment of short time (3 weeks) blunts adrenergic vasoconstriction in <10-6 mole/L of PE. Stepp and Frisbee  suggested that it is helpful to normalize blood pressure by blockade of the adrenergic receptor. Rosi may have beneficial effects in T2DM by partial attenuation (at low concentration) of adrenergic over-response in addition to the improvement of endothelial function. Rosi failed to restore the passive stress-strain relationship and did not have an effect on increased vascular stiffness after 3 weeks of treatment. Glycation and matrix deposit result from high glucose and the proliferation of vascular smooth muscle cells which might be elicited by activated α-adrenegic receptor. Rosi did not affect the plasma glucose and the expressions of α-adrenoceptor, MMP9, and elastase in the present study and hence did not restore the altered mechanical properties of the vessel wall. In fact, previous observations showed that Rosi increased body weight and did not improve systemic blood pressure, plasma glucose, cholesterol, triglycerides, free fatty acids, etc. [5, 20, 21]. The improvement of endothelial function from Rosi is not the benefit of weight loss or the reduction of glucose, triglycerides, and cholesterol. The mechanistic pathways of Rosi action requires further study.
The mechanical property of blood vessel is one of the indicators of vascular remodeling [13–17, 34, 35] and reflects the make up of extracellular matrices. Our results indicate that the blood vessel becomes stiffer if it is subjected to hyperglycemia for 6 weeks. The hardening of blood vessel is recognized as one of the mechanisms of diabetic hypertension and may result in vascular dysfunction. The treatment of Rosi for 3 weeks in this study failed to reverse the hardening of blood vessel wall and the associated remodeling indicated by the expression of MMP9 and elastase. Reddy, et al showed that treatment with ciglitazone (an agonist of PPARγ) for 8 weeks ameliorated the decrease in elastin contents . The longer term effect of Rosi on mechanical property and remodeling requires future work.
In summary, the endothelial dysfunction can be observed in as early as 19 weeks of age in ZDF rat. The adrenoceptor is activated and the remodeling of extracellular matrices is implicated in diabetic complication in early age. This study shows that Rosi treatment restores the endothelial function and adrenergic vasoconstriction at low concentration of PE. The mechanical properties along with the expressions of α-adrenoceptor, MMP9, and elastase are, however, not reversed by three weeks of Rosi treatment.
This research was supported by Lilly and company.
- Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K: Mechanisms of diabetic vasculopathy: An overview. Am J Hypertens. 2001, 14: 47-86. 10.1016/S0895-7061(00)01323-6.View ArticleGoogle Scholar
- Epstein M, Sowers JR: Diabetes mellitus and hypertension. Hypertension. 1992, 19 (5): 403-418.View ArticlePubMedGoogle Scholar
- Kaur J, Singh P, Sowers JR: Diabetes and cardiovascular diseases. Am J Ther. 2002, 9 (6): 510-515. 10.1097/00045391-200211000-00009.View ArticlePubMedGoogle Scholar
- Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE: Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008, 52 (4): 255-262. 10.1016/j.jacc.2008.03.051.View ArticlePubMedGoogle Scholar
- Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Adebara ET, Yorek MA: Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab. 2008, 10 (1): 64-74.PubMedGoogle Scholar
- Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001, 37 (4): 1053.View ArticlePubMedGoogle Scholar
- Sowers JR: Treatment of hypertension in patients with diabetes. Arch Intern Med. 2004, 164 (17): 1850-1857. 10.1001/archinte.164.17.1850.View ArticlePubMedGoogle Scholar
- Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, Ueda S, Sakanashi M, Takasu N: Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology. 2007, 148 (1): 160-165. 10.1210/en.2006-1132.View ArticlePubMedGoogle Scholar
- Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001, 104 (22): 2673-2678. 10.1161/hc4601.099485.View ArticlePubMedGoogle Scholar
- Thuillez C, Richard V: Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens. 2005, 19 (Suppl 1): S21-25. 10.1038/sj.jhh.1001889.View ArticlePubMedGoogle Scholar
- Hayden MR, Sowers JR, Tyagi SC: The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol. 2005, 4 (1): 9-10.1186/1475-2840-4-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Camp TM, Tyagi SC, Senior RM, Hayden MR, Tyagi SC: Gelatinase B (MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia. 2003, 46: 1438-1446. 10.1007/s00125-003-1200-y.View ArticlePubMedGoogle Scholar
- Liu SQ, Fung YC: Changes in the rheological properties of blood vessel tissue remodeling in the course of development of diabetes. Biorheology. 1992, 29 (5-6): 443-457.PubMedGoogle Scholar
- Liu SQ, Fung YC: Influence of STZ-induced diabetes on zero-stress states of rat pulmonary and systemic arteries. Diabetes. 1992, 41 (2): 136-146. 10.2337/diabetes.41.2.136.View ArticlePubMedGoogle Scholar
- Reddy HK, Koshy SK, Foerst J, Sturek M: Remodeling of coronary arteries in diabetic patients-an intravascular ultrasound study. Echocardiography. 2004, 21 (2): 139-144. 10.1111/j.0742-2822.2004.03014.x.View ArticlePubMedGoogle Scholar
- Reddy HK, Koshy SK, Wasson S, Quan EE, Pagni S, Roberts AM, Joshua IG, Tyagi SC: Adaptive-outward and maladaptive-inward arterial remodeling measured by intravascular ultrasound in hyperhomocysteinemia and diabetes. J Cardiovasc Pharmacol Ther. 2006, 11 (1): 65-76. 10.1177/107424840601100106.View ArticlePubMedGoogle Scholar
- Zhao J, Lu X, Zhuang F, Gregersen H: Biomechanical and morphometric properties of the arterial wall referenced to the zero-stress state in experimental diabetes. Biorheology. 2000, 37 (5-6): 385-400.PubMedGoogle Scholar
- Martinez-Lemus LA, Wu X, Wilson E, Hill MA, Davis GE, Davis MJ, Meininger GA: Integrins as unique receptors for vascular control. J Vasc Res. 2003, 40 (3): 211-233. 10.1159/000071886.View ArticlePubMedGoogle Scholar
- Peterson RG, Shaw WN, Neel MA, Little LA, Eichberg J: Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. Ilar News. 1990, 32: 16-19.View ArticleGoogle Scholar
- Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM: Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes. 2005, 54 (2): 554-562. 10.2337/diabetes.54.2.554.View ArticlePubMedGoogle Scholar
- Mittermayer F, Schaller G, Pleiner J, Krzyzanowska K, Kapiotis S, Roden M, Wolzt M: Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab. 2007, 92 (7): 2574-80. 10.1210/jc.2006-2130.View ArticlePubMedGoogle Scholar
- Laughlin MH, Turk JR, Schrage WG, Woodman CR, Price EM: Influence of coronary artery diameter on eNOS protein content. Am J Physiol Heart Circ Physiol. 2003, 284 (4): H1307-1312.View ArticlePubMedGoogle Scholar
- Lu X, Kassab GS: Vasoactivity of blood vessels using a novel isovolumic myograph. Ann Biomed Eng. 2007, 35 (3): 356-66. 10.1007/s10439-006-9243-0.View ArticlePubMedGoogle Scholar
- Stepp DW, Frisbee JC: Augmented adrenergic vasoconstriction in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol. 2002, 282 (3): H816-820.View ArticlePubMedGoogle Scholar
- Faber JE, Szymeczek CL, Cotecchia S, Thomas SA, Tanoue A, Tsujimoto G, Zhang H: Alpha1-adrenoceptor-dependent vascular hypertrophy and remodeling in murine hypoxic pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2007, 292 (5): H2316-2323. 10.1152/ajpheart.00792.2006.View ArticlePubMedGoogle Scholar
- Struijker-Boudier HA, Smits JF, De Mey JG: Pharmacology of cardiac and vascular remodeling. Annu Rev Pharmacol Toxicol. 1995, 35: 509-539. 10.1146/annurev.pa.35.040195.002453.View ArticlePubMedGoogle Scholar
- Teeters JC, Erami C, Zhang H, Faber JE: Systemic alpha 1A-adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery. Am J Physiol Heart Circ Physiol. 2003, 284 (1): H385-392.View ArticlePubMedGoogle Scholar
- Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P: In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004, 27 (2): 484-490. 10.2337/diacare.27.2.484.View ArticlePubMedGoogle Scholar
- Vinik AI, Stansberry KB, Barlow PM: Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus. J Diabetes Complications. 2003, 17 (5): 279-285. 10.1016/S1056-8727(03)00006-0.View ArticlePubMedGoogle Scholar
- Johns DG, Ao Z, Eybye M, Olzinski A, Costell M, Gruver S, Smith SA, Douglas SA, Macphee CH: Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat. J Pharmacol Exp Ther. 2005, 315 (3): 1020-1027. 10.1124/jpet.105.090993.View ArticlePubMedGoogle Scholar
- Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004, 89 (6): 2728-35. 10.1210/jc.2003-032103.View ArticlePubMedGoogle Scholar
- Naoumova RP, Kindler H, Leccisotti L, Mongillo M, Khan MT, Neuwirth C, Seed M, Holvoet P, Betteridge J, Camici PG: Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2007, 50 (21): 2051-2058. 10.1016/j.jacc.2007.07.070.View ArticlePubMedGoogle Scholar
- Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL: Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation. 2003, 108 (22): 2805-2811. 10.1161/01.CIR.0000097003.49585.5E.View ArticlePubMedGoogle Scholar
- Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993, 362: 801-809. 10.1038/362801a0.View ArticlePubMedGoogle Scholar
- Rozanski A, Qureshi E, Bauman M, Reed G, Pillar G, Diamond GA: Peripheral Arterial Responses to Treadmill Exercise Among Health Subjects and Atherosclerotic Patients. Circulation. 2001, 103 (16): 2084-2089.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.